{"id":3336,"date":"2026-11-09T15:43:58","date_gmt":"2026-11-09T15:43:58","guid":{"rendered":"https:\/\/www.arcgroup.io\/oxford\/?p=3336"},"modified":"2026-11-09T15:43:59","modified_gmt":"2026-11-09T15:43:59","slug":"abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences","status":"publish","type":"post","link":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/11\/09\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\/","title":{"rendered":"Abbvie Makes Brookfield&#8217;s ARC Oxford it&#8217;s Home as Part of More Than \u00a3120M Investment in UK Life Sciences"},"content":{"rendered":"<h2 class=\"wp-block-post-title\">Abbvie Makes Brookfield&#8217;s ARC Oxford it&#8217;s Home as Part of More Than \u00a3120M Investment in UK Life Sciences<\/h2>\n\n\n<!-- Back button -->\n<div class=\"back-button-block__container\">\n\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/community\/\" class=\"back-button-block\">\n\t\t<svg class=\"back-button-block__arrow\" width=\"13\" height=\"13\">\n\t\t\t<use xlink:href=\"#small-arrow\"><\/use>\n\t\t<\/svg>\n\t\tBack to Community\t<\/a>\n<\/div>\n\n\n\n<section class=\"feature-banner\" id=\"block_c51614b51afd5cf46cb0f5e4ae45f89f\"> \n    <div class=\"feature-banner__container\">\n            <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/11\/5510-15-scaled-1.jpg 2560w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/11\/5510-15-scaled-1-300x200.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/11\/5510-15-scaled-1-1024x683.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/11\/5510-15-scaled-1-768x512.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/11\/5510-15-scaled-1-1000x667.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(max-width: 768px) 768px, (max-width: 1024px) 1024px, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/11\/5510-15-scaled-1.jpg\" \/>\n            <\/picture>\n\n    <\/div>\n<\/section>\n\n\n<h2 class=\"wp-block-post-title\">Abbvie Makes Brookfield&#8217;s ARC Oxford it&#8217;s Home as Part of More Than \u00a3120M Investment in UK Life Sciences<\/h2>\n\n\n    <ul class=\"ed-post-categories\">\n                    <li class=\"arc-orange\">\n                <a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/category\/news\/\">News<\/a>\n            <\/li>\n                    <li class=\"arc-purple\">\n                <a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/category\/corporate\/\">Corporate<\/a>\n            <\/li>\n            <\/ul>\n\n\n<h2 class=\"wp-block-post-title\">Abbvie Makes Brookfield&#8217;s ARC Oxford it&#8217;s Home as Part of More Than \u00a3120M Investment in UK Life Sciences<\/h2>\n\n\n<p class=\"wp-block-paragraph\">AbbVie, has announced the expansion of its UK R&amp;D facility, AbbVie Oxford. The new 12,000 sq. ft site at ARC Oxford will expand AbbVie\u2019s research capabilities across immunology, neuroscience and oncology.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The opening builds on capabilities established through AbbVie\u2019s acquisition of Oxford-founded biotechnology company DJS Antibodies in October 2022 and combines the agility and entrepreneurial spirit of a biotech with the scale and expertise of AbbVie&#8217;s worldwide R&amp;D network. It forms part of more than \u00a3120 million invested and committed to scientific research, academic collaborations and talent development across the UK life sciences ecosystem.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;AbbVie Oxford is expanding to further harness the leading life sciences ecosystem in Oxford that brings together academic and clinical expertise and strong scientific talent,\u201d said Jon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. \u201cHuman biology and reverse translation are fundamental to our approach for identifying promising disease targets and combination therapies to advance potential new medicines for people living with serious diseases where significant unmet needs remain. This investment will help us build on that approach as we expand our scientific capabilities and deepen collaboration across the UK life sciences ecosystem.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cScientific discovery is only the beginning. Its real impact comes when innovations reach the patients who need them,\u201d said Kelly Sanderson Schrems, vice president and general manager, AbbVie UK. \u201cCountries that combine good access and uptake of innovative medicines with world-class research and development are best placed to attract global life sciences investment and improve health outcomes. The UK has made important commitments on life sciences growth. Delivering on these commitments is critical to maintaining global competitiveness and ensuring innovative medicines reach patients.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">AbbVie supports and engages with more than 100 universities and research organisations each year in the UK, supporting the broader scientific ecosystem and helping create opportunities to advance breakthrough science<em>.<\/em> One collaboration with the University of Oxford is exploring how patients with certain inflammatory conditions respond, both molecularly and clinically, to different treatments across an extended phase of their disease course, helping to guide the development of medicines in the future. AbbVie also funds a postdoctoral research programme at the University of Oxford to investigate the biological drivers of a number of inflammatory diseases.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Abbvie\u2019s new facility will sit alongside a growing community of life sciences, healthcare and technology organisations at ARC Oxford, including Perspectum, Oxford Biomedica, Oxford Biodynamics, OMass Therapeutics and Accession Therapeutics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Dan Williams, Asset Management Director at ARC Oxford, said<\/strong>:&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cWe\u2019re delighted that AbbVie has chosen ARC Oxford following its acquisition of DJS Antibodies. DJS is a great example of Oxford\u2019s strength in organic innovation \u2013 being a homegrown company whose pioneering science has attracted the backing of a global biopharmaceutical business.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;Building 5510 puts them right at the heart of the campus, a stone\u2019s throw from the new Cowley Train Line project and sitting alongside a mature community of like-minded businesses working across life sciences, healthcare and technology.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cCreating a diverse concentration of innovation is central to our vision for ARC Oxford, providing an environment where companies of all sizes can take advantage of the Campus location, infrastructure and facilities allowing them to grow and succeed.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The campus is home to an expanding life sciences ecosystem, with recent investment increasing the range of space available to science and tech businesses throughout their growth journey. This includes Motherlabs ARC\u2019s accelerator space, providing fitted laboratory space with shared services for early-stage and scaling life sciences companies, and Adapt Oxford, co working space. &nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">ARC Oxford is as a major science and innovation destination within the city of Oxford.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The arrival of AbbVie also brings further international investment into Oxford\u2019s life sciences sector, connecting locally founded innovation with the global research and development capabilities of one of the world\u2019s leading biopharmaceutical companies.<\/p>\n\n\n    <section class=\"news-archive \" id=\"block_1ca6dc76644a089b1161156fa51935f0\">\n                    <div class=\"ed-container news-archive__title ed-archive-header__title ed-archive-header__title--large\">\n                <div class=\"ed-row\">\n                    <div class=\"ed-col ed-col__half\">\n                        \n                            <h3>More News<\/h3>\n                                            <\/div>\n                    <div class=\"ed-col ed-col__half\">\n                                                    <a href=\"https:\/\/www.arcgroup.io\/oxford\/community\/\" target=\"\">\n                                View all news &rarr;\n                            <\/a>\n                                            <\/div>\n                <\/div>\n            <\/div>\n                <div class=\"ed-container\">\n            <div class=\"ed-row\">\n                \n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/10\/Omass-Therapeutics.webp 664w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/10\/Omass-Therapeutics-300x169.webp 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/10\/Omass-Therapeutics-475x267.webp 475w\" type=\"image\/webp\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/10\/Omass-Therapeutics.webp\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/10\/19\/omass-therapeutics-raises-310m\/\" target=\"_self\">\n\t\t\t\tOMass Therapeutics Raises $310M in Series C Funding to bolster its drug developments\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team.jpeg 1920w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team-300x200.jpeg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team-1024x682.jpeg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team-768x512.jpeg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team-1000x666.jpeg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/07\/Theolytics-senior-team.jpeg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/20\/biotech-theolytics-relocates-to-arc-oxford\/\" target=\"_self\">\n\t\t\t\tBiotech Theolytics Relocates to ARC Oxford\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/09\/arc-launches-adapt-by-arc-at-arc-oxford\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/0X8A5874-scaled.jpg 2560w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/0X8A5874-300x213.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/0X8A5874-1024x728.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/0X8A5874-768x546.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/0X8A5874-1000x711.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/06\/0X8A5874-scaled.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/07\/09\/arc-launches-adapt-by-arc-at-arc-oxford\/\" target=\"_self\">\n\t\t\t\tARC Launches Adapt by ARC at ARC Oxford\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n            <\/div>\n        <\/div>\n    <\/section>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie, has announced the expansion of its UK R&amp;D facility, AbbVie Oxford. The new 12,000 sq. ft site at ARC Oxford will expand AbbVie\u2019s research capabilities across immunology, neuroscience and oncology. The opening builds on capabilities established through AbbVie\u2019s acquisition of Oxford-founded biotechnology company DJS Antibodies in October 2022 and combines the agility and entrepreneurial [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":3337,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[22,30],"tags":[4276,6210],"class_list":["post-3336","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-corporate","tag-science-and-innovation","tag-life-science-and-health"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Abbvie Makes Brookfield&#039;s ARC Oxford it&#039;s Home as Part of More Than \u00a3120M Investment in UK Life Sciences - ARC Oxford<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/11\/09\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abbvie Makes Brookfield&#039;s ARC Oxford it&#039;s Home as Part of More Than \u00a3120M Investment in UK Life Sciences - ARC Oxford\" \/>\n<meta property=\"og:description\" content=\"AbbVie, has announced the expansion of its UK R&amp;D facility, AbbVie Oxford. The new 12,000 sq. ft site at ARC Oxford will expand AbbVie\u2019s research capabilities across immunology, neuroscience and oncology. The opening builds on capabilities established through AbbVie\u2019s acquisition of Oxford-founded biotechnology company DJS Antibodies in October 2022 and combines the agility and entrepreneurial [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/11\/09\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\/\" \/>\n<meta property=\"og:site_name\" content=\"ARC Oxford\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-09T15:43:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-09T15:43:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/11\/5510-15-scaled-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"rebeccabethwaite\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"rebeccabethwaite\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/11\\\/09\\\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/11\\\/09\\\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\\\/\"},\"author\":{\"name\":\"rebeccabethwaite\",\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/#\\\/schema\\\/person\\\/c38b20486f04cfec09f2a0d556de7942\"},\"headline\":\"Abbvie Makes Brookfield&#8217;s ARC Oxford it&#8217;s Home as Part of More Than \u00a3120M Investment in UK Life Sciences\",\"datePublished\":\"2026-11-09T15:43:58+00:00\",\"dateModified\":\"2026-11-09T15:43:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/11\\\/09\\\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\\\/\"},\"wordCount\":657,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/11\\\/09\\\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2026\\\/11\\\/5510-15-scaled-1.jpg\",\"keywords\":[\"Science and innovation\",\"Life science and Health\"],\"articleSection\":[\"News\",\"Corporate\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/11\\\/09\\\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/11\\\/09\\\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\\\/\",\"url\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/11\\\/09\\\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\\\/\",\"name\":\"Abbvie Makes Brookfield's ARC Oxford it's Home as Part of More Than \u00a3120M Investment in UK Life Sciences - ARC Oxford\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/11\\\/09\\\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/11\\\/09\\\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2026\\\/11\\\/5510-15-scaled-1.jpg\",\"datePublished\":\"2026-11-09T15:43:58+00:00\",\"dateModified\":\"2026-11-09T15:43:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/11\\\/09\\\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/11\\\/09\\\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/11\\\/09\\\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2026\\\/11\\\/5510-15-scaled-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2026\\\/11\\\/5510-15-scaled-1.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/2026\\\/11\\\/09\\\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abbvie Makes Brookfield&#8217;s ARC Oxford it&#8217;s Home as Part of More Than \u00a3120M Investment in UK Life Sciences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/#website\",\"url\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/\",\"name\":\"ARC Oxford\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/#organization\"},\"alternateName\":\"ARC Oxford\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/#organization\",\"name\":\"ARC Oxford\",\"alternateName\":\"ARC Oxford\",\"url\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2025\\\/06\\\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"contentUrl\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2025\\\/06\\\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"width\":2084,\"height\":2084,\"caption\":\"ARC Oxford\"},\"image\":{\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/#\\\/schema\\\/person\\\/c38b20486f04cfec09f2a0d556de7942\",\"name\":\"rebeccabethwaite\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g\",\"caption\":\"rebeccabethwaite\"},\"url\":\"https:\\\/\\\/www.arcgroup.io\\\/oxford\\\/blog\\\/author\\\/rebeccafrost\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abbvie Makes Brookfield's ARC Oxford it's Home as Part of More Than \u00a3120M Investment in UK Life Sciences - ARC Oxford","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/11\/09\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\/","og_locale":"en_US","og_type":"article","og_title":"Abbvie Makes Brookfield's ARC Oxford it's Home as Part of More Than \u00a3120M Investment in UK Life Sciences - ARC Oxford","og_description":"AbbVie, has announced the expansion of its UK R&amp;D facility, AbbVie Oxford. The new 12,000 sq. ft site at ARC Oxford will expand AbbVie\u2019s research capabilities across immunology, neuroscience and oncology. The opening builds on capabilities established through AbbVie\u2019s acquisition of Oxford-founded biotechnology company DJS Antibodies in October 2022 and combines the agility and entrepreneurial [&hellip;]","og_url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/11\/09\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\/","og_site_name":"ARC Oxford","article_published_time":"2026-11-09T15:43:58+00:00","article_modified_time":"2026-11-09T15:43:59+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/11\/5510-15-scaled-1.jpg","type":"image\/jpeg"}],"author":"rebeccabethwaite","twitter_card":"summary_large_image","twitter_misc":{"Written by":"rebeccabethwaite","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/11\/09\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\/#article","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/11\/09\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\/"},"author":{"name":"rebeccabethwaite","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/c38b20486f04cfec09f2a0d556de7942"},"headline":"Abbvie Makes Brookfield&#8217;s ARC Oxford it&#8217;s Home as Part of More Than \u00a3120M Investment in UK Life Sciences","datePublished":"2026-11-09T15:43:58+00:00","dateModified":"2026-11-09T15:43:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/11\/09\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\/"},"wordCount":657,"commentCount":0,"publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/11\/09\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/11\/5510-15-scaled-1.jpg","keywords":["Science and innovation","Life science and Health"],"articleSection":["News","Corporate"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/11\/09\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/11\/09\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\/","url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/11\/09\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\/","name":"Abbvie Makes Brookfield's ARC Oxford it's Home as Part of More Than \u00a3120M Investment in UK Life Sciences - ARC Oxford","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/11\/09\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\/#primaryimage"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/11\/09\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/11\/5510-15-scaled-1.jpg","datePublished":"2026-11-09T15:43:58+00:00","dateModified":"2026-11-09T15:43:59+00:00","breadcrumb":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/11\/09\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/11\/09\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/11\/09\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\/#primaryimage","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/11\/5510-15-scaled-1.jpg","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/11\/5510-15-scaled-1.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/11\/09\/abbvie-makes-arc-oxford-its-home-as-part-of-more-than-120m-investment-in-uk-life-sciences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.arcgroup.io\/oxford\/"},{"@type":"ListItem","position":2,"name":"Abbvie Makes Brookfield&#8217;s ARC Oxford it&#8217;s Home as Part of More Than \u00a3120M Investment in UK Life Sciences"}]},{"@type":"WebSite","@id":"https:\/\/www.arcgroup.io\/oxford\/#website","url":"https:\/\/www.arcgroup.io\/oxford\/","name":"ARC Oxford","description":"","publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"alternateName":"ARC Oxford","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arcgroup.io\/oxford\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.arcgroup.io\/oxford\/#organization","name":"ARC Oxford","alternateName":"ARC Oxford","url":"https:\/\/www.arcgroup.io\/oxford\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","width":2084,"height":2084,"caption":"ARC Oxford"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/c38b20486f04cfec09f2a0d556de7942","name":"rebeccabethwaite","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g","caption":"rebeccabethwaite"},"url":"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/rebeccafrost\/"}]}},"_links":{"self":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/3336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/comments?post=3336"}],"version-history":[{"count":1,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/3336\/revisions"}],"predecessor-version":[{"id":3338,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/3336\/revisions\/3338"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media\/3337"}],"wp:attachment":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media?parent=3336"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/categories?post=3336"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/tags?post=3336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}